Tyche Industries Ltd.
BSE: TYCHE · Pharmaceuticals · sector
₹102.00BSE close 2026-10-26
Key numbers
Market cap₹105 cr
Price₹102.00
52w high / low₹148 / ₹99
P/E23.4xSector median 27.9x
P/B0.7xSector median 2.9x
Book value₹137.1
Dividend yield2.94%Sector median 0.48%
ROE3.2%Sector median 11.7%
ROCE4.4%Sector median 12.3%
OPM-2.8%Sector median 14.0%
Debt / equity0.00xSector median 0.16x
EV/EBITDA–Sector median 18.6x
Interest cover61,510.0x
Current ratio16.46x
Sales growth 3y-10.7%Sector median +9.6%
Profit growth 3y-21.2%Sector median +13.3%
PEG–
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹75 cr vs borrowings ₹0 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 61,510.0x in the last 12 months.
- Net loss in 1 of the last 6 quarters.
- Other income was 218% of net profit in the last 12 months.
- Dividend paid in 4 of the last 5 financial years.
- Price ₹102.00 on 2026-10-26: -31.1% from the 52-week high, +3.0% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹209.65 · low ₹102.00
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|
| Revenue | 12 | 13 | 14 | 11 | 16 | 9 |
| EBITDA | -0 | 2 | -0 | 1 | -1 | -2 |
| OPM % | -1.4% | 15.4% | -0.9% | 10.3% | -4.1% | -18.7% |
| Other income | 2 | 2 | 3 | 2 | 3 | 2 |
| Net profit | 1 | 2 | 2 | 2 | 1 | -0 |
| EPS (₹) | 1.00 | 2.37 | 1.49 | 1.78 | 1.05 | 0.04 |
| Revenue YoY | +31.0% | -28.3% | ||||
| Profit YoY | +11.7% | -101.6% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 62 | 75 | 70 | 65 | 54 | 50 |
| EBITDA | 10 | 16 | 13 | 11 | 2 | -1 |
| Net profit | 9 | 14 | 12 | 12 | 7 | 4 |
| EPS (₹) | 9.17 | 13.74 | 11.78 | 12.19 | 6.70 | 4.36 |
| Revenue growth | +21.1% | -7.8% | -5.8% | -18.1% | – | |
| Profit growth | +51.9% | -13.6% | +2.0% | -44.4% | – | |
| Dividend / share (₹) | – | 1.50 | 2.00 | 2.50 | 3.00 |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -10.7% | – | – |
| Net profit | -21.2% | – | – |
| EPS | -21.3% | – | – |
| Share price | – | -24.1% (2y) | -20.0% |
Balance sheet
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Shareholders' equity | 137 | 140 |
| Borrowings | 0 | 0 |
| Cash & equivalents | 84 | 75 |
| Total assets | 147 | 148 |
| Fixed assets | 16 | 19 |
| Capital work in progress | 0 | 0 |
| Investments | 0 | 0 |
| Receivables | 17 | 20 |
| Inventory | 17 | 10 |
| Payables | 6 | 2 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY25 | FY26 |
|---|---|---|
| Cash from operations | 9 | 3 |
| Cash from investing | -1 | -9 |
| Cash from financing | -3 | -3 |
| Capex | 0 | 4 |
| Free cash flow | 9 | -1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY25 | FY26 |
|---|---|---|
| ROE % | 9.1% | 4.9% |
| ROCE % | 12.2% | 6.7% |
| Debtor days | 95 | 133 |
| Inventory days | 245 | 150 |
| Payable days | 85 | 38 |
| Cash conversion cycle (days) | 255 | 245 |
| Working capital days | 621 | 690 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| TYCHE | ₹105 cr | 23.4x | 0.7x | 3.2% | 4.4% | -2.8% | -10.7% | 2.94% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2026-09-23 | Dividend | Final Dividend Rs 3.5 |
| 2025-09-19 | Dividend | Final Dividend Rs 3.0 |
| 2024-09-20 | Dividend | Final Dividend Rs 2.5 |
| 2023-08-22 | Dividend | Dividend Rs 2.0 |
| 2022-09-22 | Dividend | Final Dividend Rs 1.5 |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | TYCHE |
| BSE code | 532384 |
| ISIN | INE443B01012 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-24 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.